QQQ   347.99 (-0.57%)
AAPL   177.25 (-0.03%)
MSFT   328.39 (-0.85%)
META   264.72 (+0.84%)
GOOGL   122.87 (-0.65%)
AMZN   120.58 (-0.89%)
TSLA   203.93 (+1.38%)
NVDA   378.34 (-5.68%)
NIO   7.53 (+1.62%)
BABA   79.58 (+1.16%)
AMD   118.21 (-5.64%)
T   15.73 (+0.58%)
F   12.00 (-4.69%)
MU   68.20 (-4.87%)
CGC   0.84 (-2.34%)
GE   101.53 (-0.86%)
DIS   87.96 (+0.16%)
AMC   4.51 (-2.59%)
PFE   38.02 (+2.73%)
PYPL   61.99 (-0.10%)
NFLX   395.23 (+0.57%)
QQQ   347.99 (-0.57%)
AAPL   177.25 (-0.03%)
MSFT   328.39 (-0.85%)
META   264.72 (+0.84%)
GOOGL   122.87 (-0.65%)
AMZN   120.58 (-0.89%)
TSLA   203.93 (+1.38%)
NVDA   378.34 (-5.68%)
NIO   7.53 (+1.62%)
BABA   79.58 (+1.16%)
AMD   118.21 (-5.64%)
T   15.73 (+0.58%)
F   12.00 (-4.69%)
MU   68.20 (-4.87%)
CGC   0.84 (-2.34%)
GE   101.53 (-0.86%)
DIS   87.96 (+0.16%)
AMC   4.51 (-2.59%)
PFE   38.02 (+2.73%)
PYPL   61.99 (-0.10%)
NFLX   395.23 (+0.57%)
QQQ   347.99 (-0.57%)
AAPL   177.25 (-0.03%)
MSFT   328.39 (-0.85%)
META   264.72 (+0.84%)
GOOGL   122.87 (-0.65%)
AMZN   120.58 (-0.89%)
TSLA   203.93 (+1.38%)
NVDA   378.34 (-5.68%)
NIO   7.53 (+1.62%)
BABA   79.58 (+1.16%)
AMD   118.21 (-5.64%)
T   15.73 (+0.58%)
F   12.00 (-4.69%)
MU   68.20 (-4.87%)
CGC   0.84 (-2.34%)
GE   101.53 (-0.86%)
DIS   87.96 (+0.16%)
AMC   4.51 (-2.59%)
PFE   38.02 (+2.73%)
PYPL   61.99 (-0.10%)
NFLX   395.23 (+0.57%)
QQQ   347.99 (-0.57%)
AAPL   177.25 (-0.03%)
MSFT   328.39 (-0.85%)
META   264.72 (+0.84%)
GOOGL   122.87 (-0.65%)
AMZN   120.58 (-0.89%)
TSLA   203.93 (+1.38%)
NVDA   378.34 (-5.68%)
NIO   7.53 (+1.62%)
BABA   79.58 (+1.16%)
AMD   118.21 (-5.64%)
T   15.73 (+0.58%)
F   12.00 (-4.69%)
MU   68.20 (-4.87%)
CGC   0.84 (-2.34%)
GE   101.53 (-0.86%)
DIS   87.96 (+0.16%)
AMC   4.51 (-2.59%)
PFE   38.02 (+2.73%)
PYPL   61.99 (-0.10%)
NFLX   395.23 (+0.57%)
NASDAQ:CARM

Carisma Therapeutics (CARM) Stock Forecast, Price & News

$5.67
+0.68 (+13.63%)
(As of 05/31/2023 ET)
Compare
Today's Range
$5.04
$5.75
50-Day Range
$2.82
$6.56
52-Week Range
$2.75
$19.30
Volume
200,800 shs
Average Volume
123,494 shs
Market Capitalization
$57.69 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$10.00

Carisma Therapeutics MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
58.7% Upside
$9.00 Price Target
Short Interest
Healthy
2.08% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.94mentions of Carisma Therapeutics in the last 14 days
Based on 11 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($2.52) to ($1.66) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.14 out of 5 stars

Medical Sector

480th out of 1,006 stocks

Pharmaceutical Preparations Industry

230th out of 492 stocks


CARM stock logo

About Carisma Therapeutics (NASDAQ:CARM) Stock

Carisma Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the discovery and development of immunotherapies. It offers chimeric antigen receptor (CAR)-macrophages, a cell therapy platform focusing on the treatment of solid tumors. The company was founded by Michael Klichinsky and Saar Gill in 2016 and is headquartered in Philadelphia, PA.

Receive CARM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Carisma Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

CARM Stock News Headlines

The 4th Military Revolution is Happening
. There have been 3 military revolutions in the past 100 years. The first was when the tank was invented in 1915. The second was the nuclear bomb in 1945. The third was the "smart bomb" in 1991. Amid the turmoil, there will be many losers. Click here to see how to win instead >>>
Carisma Therapeutics (CARM) Receives a Buy from Robert W. Baird
The 4th Military Revolution is Happening
. There have been 3 military revolutions in the past 100 years. The first was when the tank was invented in 1915. The second was the nuclear bomb in 1945. The third was the "smart bomb" in 1991. Amid the turmoil, there will be many losers. Click here to see how to win instead >>>
Carisma Therapeutics Inc (CARM)
Carisma Therapeutics (CARM) vs. Its Peers Financial Contrast
Carisma Therapeutics Inc.
CARM Carisma Therapeutics, Inc.
See More Headlines
Receive CARM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Carisma Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

CARM Company Calendar

Last Earnings
5/11/2023
Today
5/31/2023
Next Earnings (Estimated)
8/14/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:CARM
Web
N/A
Employees
N/A
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$9.00
High Stock Price Forecast
$10.00
Low Stock Price Forecast
$7.00
Forecasted Upside/Downside
+100.4%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

Net Income
$-19,880,000.00
Pretax Margin
-1,126.41%

Debt

Sales & Book Value

Annual Sales
$40 million
Cash Flow
$3.56 per share
Book Value
$8.46 per share

Miscellaneous

Free Float
9,849,000
Market Cap
$50.80 million
Optionable
Not Optionable
Beta
0.81

Key Executives

  • Steven Kelly
    President, Chief Executive Officer & Director
  • Richard Steven Morris
    CFO, Treasurer & Chief Compliance Officer
  • Michael Klichinsky
    Chief Scientific Officer
  • Daniel J. Cushing
    Chief Technology & Development Officer













CARM Stock - Frequently Asked Questions

Should I buy or sell Carisma Therapeutics stock right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Carisma Therapeutics in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" CARM shares.
View CARM analyst ratings
or view top-rated stocks.

What is Carisma Therapeutics' stock price forecast for 2023?

3 brokerages have issued 1 year price objectives for Carisma Therapeutics' shares. Their CARM share price forecasts range from $7.00 to $10.00. On average, they anticipate the company's stock price to reach $9.00 in the next year. This suggests a possible upside of 80.4% from the stock's current price.
View analysts price targets for CARM
or view top-rated stocks among Wall Street analysts.

How have CARM shares performed in 2023?

Carisma Therapeutics' stock was trading at $3.25 on January 1st, 2023. Since then, CARM shares have increased by 53.5% and is now trading at $4.99.
View the best growth stocks for 2023 here
.

When is Carisma Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, August 14th 2023.
View our CARM earnings forecast
.

How were Carisma Therapeutics' earnings last quarter?

Carisma Therapeutics, Inc. (NASDAQ:CARM) issued its earnings results on Thursday, May, 11th. The company reported ($1.93) earnings per share for the quarter. The company earned $3.24 million during the quarter.

What is Carisma Therapeutics' stock symbol?

Carisma Therapeutics trades on the NASDAQ under the ticker symbol "CARM."

Who are Carisma Therapeutics' major shareholders?

Carisma Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional investors include Group One Trading L.P. (0.00%), BML Capital Management LLC (4.04%), BlackRock Inc. (1.29%), Geode Capital Management LLC (1.17%), Susquehanna International Group LLP (0.00%) and Renaissance Technologies LLC (0.67%).

How do I buy shares of Carisma Therapeutics?

Shares of CARM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Carisma Therapeutics' stock price today?

One share of CARM stock can currently be purchased for approximately $4.99.

How much money does Carisma Therapeutics make?

Carisma Therapeutics (NASDAQ:CARM) has a market capitalization of $50.80 million and generates $40 million in revenue each year. The company earns $-19,880,000.00 in net income (profit) each year or ($3.93) on an earnings per share basis.

How can I contact Carisma Therapeutics?

Carisma Therapeutics' mailing address is 245 1st St Ste 1800, Cambridge, Massachusetts 02142-1292. The company can be reached via phone at 617-444-8550, via email at ir@sesenbio.com, or via fax at 617-858-0911.

This page (NASDAQ:CARM) was last updated on 5/31/2023 by MarketBeat.com Staff

My Account -